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Detection of Antigen-Specific T Cells
(Workshop #1, Friday 1/31/03 4:00-5:30 PM)
Jeffrey Molldrem, MD
MD Anderson Cancer Center
Houston, TX
and
Eric D. Wieder, PhD
M.D. Anderson Medical Center
Houston, TX
Both graft versus leukemia and graft versus host disease are in large part conveyed by donor T lymphocytes
contained in the graft as part of the unfolding adaptive immune response. New immunotherapy strategies that
are designed to boost graft versus leukemia and reduce graft versus host disease involve the use of deﬁned anti-
gen vaccines and adoptively transferred T lymphocytes with distinct antigen speciﬁcity. The nature of that speci-
ﬁcity is characterized by the precise interaction of the T cell receptor with its cognate peptide/MHC ligand.
Monitoring these evolving immune responses after transplantation has involved several experimental approaches,
some of which may soon be developed into commercialized standard assays for pathology laboratories. Yet, it is
still not clear which, if any, of the current assays should be relied upon to yield clinically useful information. This
workshop will focus on describing current techniques for measuring both quantitative and qualitative aspects of
the immune response, including peptide/MHC tetramers, cytokine ﬂuorescence cytometry, T cell receptor spec-
tratyping, and highly detailed T cell surface phenotyping. The potential for these assays to yield complementary
information and the controversies regarding reliability and potentially conﬂicting results will be discussed as they
relate to transplantation and immunotherapy.
Lung Injury after SCT: How Can We Improve Early Diagnosis and Treatment?
(Workshop #2, Friday 1/31/03 4:00-5:30 PM)
Kenneth R. Cooke, MD
University of Michigan Cancer Center
Ann Arbor, MI
and
Joan G. Clark, MD
Fred Hutchison Cancer Research Center
Seattle, WA
Allogeneic hematopoietic stem cell transplantation (HSCT) is an important therapeutic option for a number
of malignant and nonmalignant disorders. Unfortunately, graft-versus-host disease (GVHD) and pulmonary dys-
function limit the use of this form of therapy. Lung complications occur in 25% to 55% of HSCT recipients
and can account for approximately 40% of transplant related mortality. Fifty percent of cases are noninfectious in
origin. In this context, 2 types of pulmonary injury are recognized as signiﬁcant contributors of morbidity and
mortality: idiopathic pneumonia syndrome (IPS) and chronic obstructive lung disease (OLD).
IPS deﬁnes noninfectious lung injury that occurs in the acute setting. Diagnostic criteria for IPS include
signs and symptoms of pneumonia, diffuse radiographic inﬁltrates, and the absence of infection in the lower
respiratory tract. Although a variety of histologic ﬁndings are associated with IPS, interstitial pneumonitis is
most common. The median time to onset of IPS is within the ﬁrst 3 to 4 weeks after transplant and mortal-
ity rates range from 50% to 80% despite broad-spectrum antimicrobial agents and high-dose steroids.
OLD has been reported in up to 20% of HSCT survivors with mortality rates exceeding 50%. OLD tends
to occur later and be more insidious than IPS. Symptoms may include cough, dyspnea, and wheezing, but many
patients remain asymptomatic despite having evidence of moderate to severe obstructive physiology. Lung exams
and chest radiographs are frequently not revealing, although patients may have signs and symptoms of chronic
GVHD. Bronchiolitis obliterans (BrOb) remains the most common form of histopathology associated with OLD
and has been traditionally used to describe “GVHD of the lung.” Response to treatment with bronchodilator
and immunosuppressive therapy is limited and generally results in preservation (rather than signiﬁcant improve-
ment) of existing lung function, suggesting that early detection of disease is important.
This seminar will discuss what is known about the pathophysiology of IPS and OLD and will focus on
strategies to improve the evaluation, diagnosis, and treatment of pulmonary dysfunction after HSCT.
Clinical Trials: Statistical Questions and Answers
(Workshop #3, Friday 1/31/03 4:00-5:30 PM)
John P. Klein, PhD
Medical College of Wisconsin
Milwaukee, WI
and
Glenn Heller, PhD
Memorial Sloan-Kettering Cancer Center
New York, NY
This workshop will examine statistical issues that are of importance in the design and conduct of clinical
trials in bone marrow transplantation. We shall discuss in detail designs for phase II trials and problems
associated with biological assignment trials.
Phase II experimental designs are developed to gain information about the feasibility and safety of the
treatments, and to provide initial estimates of treatment efﬁcacy. The primary objective of this phase II
screening design is to determine whether the probability of a nonleukemic event induced by the experimen-
tal treatment is sufﬁciently low to warrant further study. The nonleukemic events under observation are:
graft-versus-host disease, graft failure, and treatment-related mortality. The design will provide preliminary
evidence of treatment efﬁcacy. However, in order to reduce patient risk, the study design includes an early
termination mechanism if excessive nonleukemic events occur during the accrual period.
The design is intended to screen for treatments that restrict the level of nonleukemic events. It is well suited
to studies in the area of allogeneic transplantation, where there are several promising treatments waiting to be
tested, but a slow accrual of patients. It provides strict criteria for success in terms of nonleukemic events,
thereby hastening elimination of nonoptimal treatments. The rationale stems from the principle that a reduction
in nonleukemic events to minimal levels is a sufﬁcient condition for a successful transplant treatment.
Biological assignment trials are those in which patients with a suitable donor are assigned to an alloge-
neic transplant and those without are assigned to an autologous transplant. The rationale for such trials is
often the fact that there are not enough patients with suitable donors to perform a randomized trial. We
shall discuss problems and advantages of such trials. Potential problems include physician selection bias, pa-
tient bias, problems with the timing of the assignment, and possible problems with consent. Advantages in-
clude a substantial increase in sample sizes available for treatment comparison.
PBSC from Unrelated Donors: Can We Exploit the Large Numbers of Growth Factor-Mobilized
Hematopoietic Progenitor Cells to Improve Post-Transplantation Outcomes?
(Workshop #4, Sunday 2/2/03 4:00-5:30 PM)
Claudio Anasetti, MD
Fred Hutchinson Cancer Research Center
Seattle, WA
and
Dennis Confer, MD
National Marrow Donor Program
Minneapolis, MN
High doses of hematopoietic progenitor cells in allogenic marrow grafts have been correlated with ro-
bust hematopoietic engraftment and decreased mortality from infectious complications. Peripheral blood
stem cell products (PBSC) collected after mobilization with granulocyte-colony stimulating factor (G-CSF)
contain a larger number of CD34-positive progenitors and total cells compared with marrow. These obser-
vations have raised the hypothesis that PBSC transplantation will lead to lower mortality compared with
marrow transplantation. In addition, PBSC grafts contain higher numbers of T cells, predicting a more
powerful antileukemia effect. However, PBSC may lead to increased incidence and severity of acute and
chronic graft-versus-host disease (GVHD). This concern is especially serious when the donor is unrelated.
Eight randomized trials compared transplantation of mobilized PBSC and marrow from HLA-identical sib-
ling donors. PBSC led to a more rapid engraftment of neutrophils and platelets but also to an increased
incidence of acute or chronic GVHD in some of the trials. Survival was improved with PBSC in only two
of the trials, but in no instance was marrow superior to PBSC. Initial reports have demonstrated the feasi-
bility and potential safety of mobilized PBSC transplants from unrelated donors, but without apparent dif-
ferences in survival. Although the beneﬁts and risks of PBSC transplants from unrelated donors are uncer-
tain, the utilization of unrelated donor PBSC in the U.S. is increasing over time from 223 in the year 2000
to 372 in the year 2001. The continued rise in utilization of PBSC, in the absence of deﬁnitive data demon-
strating any long-term advantages over marrow, supports the rationale for the timely conduct of a prospec-
tive randomized trial of PBSC versus marrow in unrelated donor transplantation.
Assessing Quality of Life Workshop
(Workshop #6, Sunday 2/2/03 4:00-5:30 PM)
Stephanie J. Lee, MD, MPH
Dana-Farber Cancer Institute
Boston, MA
and
Gerard Socie, MD, PhD
Service d’He´matologie/Greffe de Moelle, Hoˆpital Saint Louis,
Paris, France
Quality of life (QOL) is determined by many factors including physical abilities, symptoms, social well-
being, psycho-emotional status, and spiritual/existential experiences. It reﬂects how well people feel, what
they can accomplish, how satisﬁed they are with their lives, and whether their lives have meaning and pur-
pose. Within this broad concept, health-related quality of life (HRQOL) refers to aspects of QOL that are
attributable to health, disease, or medical treatment.
After hematopoietic cell transplantation (HCT), negative aspects of QOL generally relate to slow
or incomplete physical recovery and difﬁculty reassuming social roles. Positive changes emphasize a
greater appreciation for family and life. Survivors generally report high global quality of life following
HCT, but also report many speciﬁc symptoms and limitations on their daily activities. In particular,
1. Physical: HCT patients, especially those suffering from chronic graft-versus-host disease (cGVHD),
report lower physical functioning and poorer overall health than the general population. HCT can
be associated with a variety of irreversible physical sequelae including cataracts, premature meno-
pause, infertility, avascular necrosis of bone, and other organ complications. Many of the medica-
tions prescribed after HCT have bothersome side effects.
2. Psycho-emotional (eg, anxiety, depression, fear): Reported rates of psychiatric diagnoses are high,
including a 20%-30% incidence of depression and a 5% incidence of posttraumatic stress disorder.
Worries about relapse and fears about failing to recover to pretransplantation functioning are com-
mon.
3. Social functioning (eg, relationships, roles and leisure activities): Social relationships may be en-
hanced initially after HCT but may deteriorate with time. Dissatisfaction with appearance is com-
mon. Sexual problems are also very common, with women reporting more difﬁculties than men.
4. Functional (eg, work, sleep): Approximately 60%-90% of HCT survivors eventually return to work,
with higher rates noted in ofﬁce workers compared with people employed in physically demanding
jobs. Concerns over ﬁnances and obtaining health insurance are common after HCT, as they are for
other cancer survivors. Sleep difﬁculties are also noted.
5. Spiritual/existential (eg, religion, spirituality, hope, and the meaning of life): Many report a greater
appreciation for life compared with patients not treated with HCT. Looking at survival as a second
chance for a different, perhaps more meaningful life can accentuate QOL, while struggling to regain
a lifestyle and outlook similar to before HCT may lead to dissatisfaction.
In 1999, it was estimated that there were over 20,000 patients surviving more than 5 years after HCT.
Most studies report very good health and adaptation, although up to 31% of survivors report serious func-
tional limitations or poor QOL. Better post-HCT adaptation and QOL are predicted by younger age, male
sex, higher educational level, better quality of life and social support at the time of HCT, longer time since
HCT, and absence of late complications including chronic GVHD. Very few modiﬁable factors have been
associated with post-HCT QOL.
Most interventions to improve QOL either have not been tested in clinical trials, have failed to
show signiﬁcant improvements over standard practice, or were only intended to inﬂuence QOL during
the immediate peritransplant period. These include fostering realistic expectations about recovery af-
ter HCT, helping patients retain personal control during HCT, integration of psychosocial providers
into the medical team, and aerobic exercise or relaxation imagery. Dr. Karen Syrjala at the Fred
Hutchinson Cancer Research Center is testing the efﬁcacy of a counseling intervention in a multicenter
study.
Advances in QOL research and inﬂuence on clinical practice will depend on several factors: (1) develop-
ment of successful interventions that maintain or improve QOL; (2) incorporation of QOL endpoints
alongside clinical trials to help present a balanced picture of outcomes; and (3) translation of QOL results
into meaningful data accessible and inﬂuential to clinicians, patients and policy makers. Two ongoing large,
multicenter studies typify these goals: (1) a randomized trial of T cell depletion versus immunosuppressive
medications for acute GVHD prophylaxis in which QOL is a secondary endpoint (sponsored by the Na-
tional Heart, Lung and Blood Institute); and (2) a study organized through the International Bone Marrow
Transplant Registry and the University of Florida concurrently studying long-term survivors, spouses and
controls.
This Keystone workshop on assessing QOL after HCT will focus on the following 3 interrelated
themes: (1) How should QOL information be used in medical decision making and clinical care? (2) What
types of QOL research are needed? (3) How can the transplant community support and improve QOL re-
search?
Using Registry Data for Clinical Studies
(Workshop #7, Monday 2/3/03 10:30 AM-12:00 PM)
Daniel Weisdorf, MD
University of Minnesota
Minneapolis, MN
and
Olle Ringde´n, MD
Huddinge Hospital
Stockholm, Sweden
In this session emphasis will be placed on the methods and applicability of using IBMTR/ABMDR data
to answer clinical questions in transplantation. A brief review of available data, registry methods, and suit-
able topics for analysis will be presented. Investigators will present working examples of registry analyses
that are in progress or were recently performed. Drs. Olle Ringde´n, Hillard Lazarus, and Martin Tallman
will review the speciﬁc steps and opportunities involved in studies performed with the registry.
Workshop participants will have the opportunity to pose questions, learn about registry procedures, and
discuss opportunities for participation in registry analysis. An open interactive exchange with workshop par-
ticipants is invited, and participants may suggest potential registry studies for group comment and informal
critique.
BMT Clinical Trials: What’s New?
(Workshop #8, Monday 2/3/03 10:30 AM-12:00 PM)
John Wingard, MD
University of Florida College of Medicine
Gainesville, FL
and
Jane Apperley, MBChB
Imperial College School of Medicine
London, United Kingdom
Incremental improvements in outcomes after blood and marrow transplantation have occurred over the past
several decades. Estimates from registry data are that long-term survival has increased approximately 10% per
decade. Much of the advances are attributable to improved measures to control graft-versus-host disease. Ad-
vances in antimicrobial strategies to control infectious complications have also contributed. New HLA matching
techniques have allowed better donor selection for unrelated transplantation, reducing risks and facilitating
greater use of this as a BMT option. New sources of stem cells (from peripheral blood and cord blood) offer
greater ﬂexibility for transplant clinicians to customize the treatment to individual donor and recipient needs.
Testing of new therapies in phase III randomized trials has been limited because of the small numbers
of transplants at any given center. This numerical barrier is further complicated by the heterogeneity in
transplant type, disease, disease status, stem cell source, age, and other key factors that inﬂuence transplant
outcome and may complicate the primary outcome variable to be tested in a trial; these factors may also
confound the analysis by being competing causes of death or morbidity. Transplant registries have played
important roles in teasing out some of these interrelated factors that can inﬂuence key outcomes. However,
retrospective analyses of transplant data have their limitations.
Reliance on multicenter collaborations is essential for prospective testing of new therapies and treatment strategies.
Several developments have taken place to allow prospective phase III trials. In Europe, several national networks have
organized important studies, and a focus of the EBMT has been to organize phase III studies. In the U.S., several cen-
ters have banded together for speciﬁc trials. Recently the NHLBI and NCI have jointly collaborated to fund a BMT
clinical trials network with the primary mission being to implement phase III trials of high scientiﬁc merit. The net-
work is now developing phase III trials, the ﬁrst of which will be implemented in 2003.
In this workshop, we will highlight several trials which have recently been completed. The ﬁrst reports
of these trials will have already been made. We intend to give the presenters an opportunity to update the
study, present separate analyses other than those initially presented, and to allow open discussion of some of
the important insights or controversies raised by the data. The workshop leaders will be evaluating studies
being presented in the fall of 2002 to identify the selected papers.
Terrorism: Responding to Life-Threatening Radiation Exposure
(Workshop #9, Monday 2/3/03 10:30 AM-12:00 PM)
Dennis L. Confer, MD
National Marrow Donor Program
Minneapolis, MN
Mettler and Voeltz, in a recent review of the medical response to radiation exposure, concluded, “Bone
marrow transplantation has not been helpful.” History demonstrates, however, that in every serious radia-
tion event, hematopoietic cell transplantation (HCT) has uniformly been one of the earliest therapeutic in-
terventions. Severe hematopoietic failure can be rapidly fatal irrespective of injuries to other organ systems,
and with HCT the technology to restore normal hematopoiesis is readily available.
In responding to disasters, physicians are loath to withhold initial treatment based on the uncertainty of
ultimate beneﬁt. Radiation disasters have been sufﬁciently infrequent and the advances in HCT sufﬁciently
robust to argue that the past history of results is irrelevant. Furthermore, following large-scale exposure to
radiation from a nuclear bomb or a terrorist attack, a decision to withhold sophisticated support for the
more seriously exposed victims would likely meet with public criticism.
That HCT may, indeed, be beneﬁcial was clearly demonstrated by the efforts to rescue 2 seriously ex-
posed victims of the Tokaimura incident in 1999. Both men were transplanted, one with sibling peripheral
blood progenitor cells (PBPC) and the other with unrelated donor cord blood. Engraftment of donor cells
was evident in both men who ultimately recovered autologous hematopoiesis. The heroic and unprece-
dented efforts of Japanese physicians sustained both men far longer than ever expected and provided a tem-
plate for future care of serious radiation injuries.
Several issues must be addressed in planning the transplant community’s response to radiation injuries
or other marrow toxic exposures. These include at least the following:
● Triage and transport of the injured—First responders and receiving hospitals must identify candidates for medical
support at tertiary transplant facilities. Mechanisms for transportation of these individuals must be anticipated.
● Dosimetry estimations—The window between acutely sublethal irradiation and fatal multiorgan injury is narrow.
Numerous methods for estimating exposures are available, but these must be disseminated into the community before
they are needed.
● Decontamination and isolated procedures—fear and apprehension among health care providers present a serious threat
to radiation victims. Failure to care promptly for nonradiation injuries may itself be life-threatening.
● Pretransplant and nontransplant care and support—with proper support, many patients will recover without HCT.
● Search for related and unrelated HCT donors—processes and logistics for potentially large-scale HLA typing must be
anticipated. Procurement and transportation of grafts require intense planning.
● Selection of appropriate hematopoietic graft sources—marrow, PBPC, and placental/umbilical cord blood each present
advantages and limitations that must be considered in planning for HCT support.
● Transplantation protocols and strategies—uncontrolled radiation exposure is a poor transplant preparative regimen.
Strategies for additional immunosuppression and GVHD prophylaxis are essential.
● Data collection—decisions about appropriate data collection need to be made in advance.
● Staff training and education—transplant center staff should participate in carefully created, minimally intrusive
educational programs to prepare for low-probability emergencies.
● Media communications—plans for addressing the media and the public are essential and must be prepared in advance
of the crisis situation.
This workshop will address these and other issues relevant to the transplant community’s role in homeland
security.
